Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company in Japan. The company’s drugs are marketed in approximately 90 countries worldwide. The company has an international marketing network, including Japan and 13 overseas bases in the U.S., Europe, and Asia. From these bases, the company markets its original products, such as the anti-prostatic cancer agent leuprolide acetate (marketed as Lupron Depot, Enantone, Prostap, and Leuplin), the anti-peptic ulcer agent lansoprazole (marketed as Prevacid, Ogast, Takepron, and other names), the anti-hypertensive agent candesartan cilexetil (marketed as Blopress, Kenzen, and Amias), and the anti-diabetic agent pioglitazone hydrochloride (marketed as Actos). Segments The company operates its business in two categories, Pharmaceutical business and Other businesses. The Pharmaceutical business represents the ethical drug business and healthcare business. Other businesses include business activities involving the production and marketing of a range of products, including vitamin bulks, test reagents & clinical diagnostics, photographic chemicals, and inorganic chemicals. Products Candesartan Cilexetil Candesartan cilexetil is an angiotensin receptor blocker (ARB) that is used in hypertension treatment. Its once-daily dosing provides patients with a mild anti-hypertensive action. In addition, candesartan cilexetil is also applied for the treatment of chronic heart failure. Pioglitazone Hydrochloride Once-daily dosing with pioglitazone hydrochloride improves insulin sensitivity and reduces blood glucose levels, without placing any additional burdens on the pancreas. The drug is marketed in approximately 80 countries worldwide. In the United States, Actoplus Met, a fixed-dose combination tablet of pioglitazone hydrochloride and metformin, as well as Duetact, a fixed-dose combination tablet of pioglitazone hydrochloride and glimepiride, are also marketed. Strategic Partnerships The company, in September 2007, entered into partnership with H. Lundbeck A/S for the development and commercialization of Lundbeck's portfolio of compounds, Lu AA21004, for the treatment of mood and anxiety disorders and entering Phase III studies in December 2007. This belongs to a new chemical class, with an active mechanism that differs from antidepressants. In November 2009, Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. announced that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications. The agreement includes products to be developed from Amylin's pipeline, including pramlintide/metreleptin and davalintide, which are compounds currently in phase 2 development for treatment of obesity. In January 2009, Seattle Genetics Inc. and Takeda Oncology with its parent company Takeda Pharmaceutical Co. Ltd. entered into an agreement to globally develop and commercialize brentuximab vedotin (SGN-35). History Takeda Pharmaceutical Company Limited was founded in 1781.
takeda pharmaceutical co ltd
(TKPHF:OTC Markets Group Inc - Current Information)
12-10, Nihonbashi 2-chome
Phone: 81 3 3278 2111
Fax: 81 3 3278 2000www.takeda.com
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for TKPHF.|
|View Industry Companies|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact TAKEDA PHARMACEUTICAL CO LTD, please visit www.takeda.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.